RxDoctor Payments Data

Michelle Bauhaus

Acute Care · Tulsa, OKNPI 1821766239

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Penumbra, Inc. accounts for 70.3% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $4,763, more than ten times the $92 reported in 2021. Among acute care clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,367in general payments, 2019–2025

Across 71 payments — averaging $75.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$4K
  • Stryker$376
  • Surmodics, Inc.$143
  • Alnylam Pharmaceuticals Inc.$134
  • Merck$108
  • Novo Nordisk$102
  • plus $730 from 18 others

What the payments were for

  • Speaking & faculty fees$1,50028%
  • Travel & lodging$1,60730%
  • Food & beverage$2,26042%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,367 in reported general payments places this provider in the 90th percentile of 266 acute care providers in Oklahoma.

See all acute care providers in Oklahoma

Other acute care in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →